Entity Details

Primary name EPO_HUMAN
Entity type UniProt
Source Source Link

Details

AccessionP01588
EntryNameEPO_HUMAN
FullNameErythropoietin
TaxID9606
Evidenceevidence at protein level
Length193
SequenceStatuscomplete
DateCreated1986-07-21
DateModified2021-06-02

Ontological Relatives

GenesEPO

GO terms

Show/Hide Table
GOName
GO:0000122 negative regulation of transcription by RNA polymerase II
GO:0005125 cytokine activity
GO:0005128 erythropoietin receptor binding
GO:0005179 hormone activity
GO:0005576 extracellular region
GO:0005615 extracellular space
GO:0006915 apoptotic process
GO:0006953 acute-phase response
GO:0007165 signal transduction
GO:0007566 embryo implantation
GO:0007568 aging
GO:0008015 blood circulation
GO:0008284 positive regulation of cell population proliferation
GO:0009651 response to salt stress
GO:0009986 cell surface
GO:0010523 negative regulation of calcium ion transport into cytosol
GO:0010976 positive regulation of neuron projection development
GO:0014068 positive regulation of phosphatidylinositol 3-kinase signaling
GO:0018105 peptidyl-serine phosphorylation
GO:0030218 erythrocyte differentiation
GO:0030295 protein kinase activator activity
GO:0032496 response to lipopolysaccharide
GO:0033189 response to vitamin A
GO:0033574 response to testosterone
GO:0038162 erythropoietin-mediated signaling pathway
GO:0042104 positive regulation of activated T cell proliferation
GO:0042531 positive regulation of tyrosine phosphorylation of STAT protein
GO:0042541 hemoglobin biosynthetic process
GO:0043249 erythrocyte maturation
GO:0043627 response to estrogen
GO:0044297 cell body
GO:0045666 positive regulation of neuron differentiation
GO:0045893 positive regulation of transcription, DNA-templated
GO:0046579 positive regulation of Ras protein signal transduction
GO:0048678 response to axon injury
GO:0051602 response to electrical stimulus
GO:0055093 response to hyperoxia
GO:0061418 regulation of transcription from RNA polymerase II promoter in response to hypoxia
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0070555 response to interleukin-1
GO:0071474 cellular hyperosmotic response
GO:0071548 response to dexamethasone
GO:1901215 negative regulation of neuron death
GO:1902219 negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress
GO:1902251 negative regulation of erythrocyte apoptotic process
GO:2001258 negative regulation of cation channel activity

Subcellular Location

Show/Hide Table
Subcellular Location
Secreted

Domains

Show/Hide Table
DomainNameCategoryType
IPR001323 Erythropoietin/thrombopoietinFamilyFamily
IPR003013 ErythropoietinFamilyFamily
IPR009079 Four-helical cytokine-like, coreFamilyHomologous superfamily
IPR019767 Erythropoietin/thrombopoeitin, conserved siteSiteConserved site

Diseases

Show/Hide Table
Disease IDSourceNameDescription
617907 OMIMErythrocytosis, familial, 5 (ECYT5)An autosomal dominant disorder characterized by elevated serum hemoglobin and hematocrit. Some patients have increased serum erythropoietin levels. The disease is caused by variants affecting the gene represented in this entry.
617911 OMIMDiamond-Blackfan anemia-like (DBAL)An autosomal recessive hematologic disease characterized by severe red cell hypoplastic anemia, selective absence of red cell precursors and progenitors seen on bone marrow biopsy, and increased serum erythropoietin. The disease is caused by variants affecting the gene represented in this entry.
612623 OMIMMicrovascular complications of diabetes 2 (MVCD2)Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. Disease susceptibility is associated with variants affecting the gene represented in this entry.